Story perspectives

Serum Institute Develops H5N1 Vaccine with $16.4M Funding

10/15/2025

45 6

Summary

Story summary

The Serum Institute of India (SII) is developing a baculovirus vaccine platform to target H5N1 bird flu, funded with $16.4 million from CEPI.
Initiative aims to produce a recombinant protein vaccine using wild-type and AI-optimized H5 antigens.
SII will collaborate with CEPI and the Houston Methodist Research Institute to test rapid-response capabilities and promote equitable vaccine access for vulnerable groups in the Global South, under CEPI's 100 Days Mission.

1 of 1

Story summary

The Serum Institute of India (SII) is developing a baculovirus vaccine platform to target H5N1 bird flu, funded with $16.4 million from CEPI.
Initiative aims to produce a recombinant protein vaccine using wild-type and AI-optimized H5 antigens.
SII will collaborate with CEPI and the Houston Methodist Research Institute to test rapid-response capabilities and promote equitable vaccine access for vulnerable groups in the Global South, under CEPI's 100 Days Mission.